Leading the Way on Serious & Rare Diseases
We are a global biotechnology leader focused on serving patients’ needs. Our scientists use the latest technologies to develop and deliver innovative therapies that are used to treat serious and rare diseases, including immunodeficiency and autoimmune diseases, hereditary and acquired bleeding disorders, chronic inflammatory demyelinating polyneuropathy (CIDP), hereditary angioedema (HAE), and Alpha 1 antitrypsin deficiency, as well as transplantation and critical care.
Rare Disease Patient Organizations and CSL Behring
In Europe, CSL Behring partners with EURORDIS, the European Organization for Rare Diseases. EURORDIS is a patient-driven alliance of representatives from patient organizations and others active in the field of rare diseases. EURORDIS’ mission is to build a strong pan-European community of patient organizations and people living with rare diseases, to be their voice at the European level, and -- directly or indirectly -- to fight against the impact of rare diseases on their lives.
As a Member of the EURORDIS Round Table of Companies (ERTC) at the Ruby level, CSL Behring gave EURORDIS an unrestricted grant to support its communications activities. In addition, CSL Behring also contributed in the context of the EURORDIS Black Pearl Awards, the EURORDIS Membership Meeting (EMM) and the EURORDIS International Initiatives.
In the United States, CSL Behring partners with the National Organization for Rare Disorders (NORD), an umbrella organization of patient advocacy organizations dedicated to individuals with rare diseases. NORD, along with its more than 260 patient organization members, is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services. CSL Behring serves on the NORD Corporate Council, a group of innovative companies who have and are developing therapies for the treatment of rare disorders, which helps to find commonality and discuss legislative activity to ensure the continued development of rare disease therapies. CSL Behring has provided NORD with unrestricted grants in support of their annual Rare Disease Summit and to bolster its government affairs capabilities.
CSL Behring has been recognized by NORD over the years for manufacturing cutting-edge therapies, winning its Industry Innovation Award on multiple occasions, most recently in 2017 for the licensure of IDELVION®, a long-lasting recombinant factor IX therapy for the treatment of hemophilia B.
Partnering with Advocacy Groups
CSL Behring is a global member of the Plasma Protein Therapeutics Association (PPTA), an advocacy group that works to ensure accessibility and affordability of therapies, engages in dialogue with regulatory agencies and collaborates with patient advocacy organizations. The PPTA is increasing awareness of the benefits of lifesaving medicines with its How is Your Day? campaign -- designed to inform and educate decision makers and the general public worldwide.
Rare Disease Day
CSL Behring supports International Rare Disease Day to raise awareness among policy makers and the public at large regarding the impact of rare diseases on patients' lives.Visit RareDiseaseDay.org